Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection

Abstract

Previous studies of HIV-infected women with high-risk behavior have indicated that neither neutralizing antibody nor cellular immunity elicited by an initial HIV-1 infection is associated with protection against superinfection with a different HIV-1 strain. Here, we measured antibody-dependent cell-mediated virus inhibition (ADCVI) antibody activity in the plasma of 12 superinfected cases and 36 singly infected matched controls against 2 heterologous viruses. We found no association between plasma ADCVI activity and superinfection status. ADCVI antibody activity against heterologous virus elicited by the original infection may not contribute to preventing a superinfecting HIV-1.

Figure 1

Correlation between ADCVI assays run on separate days with different effector cell donors. Plasma samples were tested against CEM.NKR-CCR5 cells infected with either HIV-1_BS208.B1 (A) or HIV-1_Q23XhoΔXho (B) on two separate occasions and with different effector cell donors. Data are shown as logit-transformations of mean % virus inhibition. ADCVI activity for each subject (represented by a unique symbol and line) with each effector cell donor is also shown (C). Each plasma sample was run in triplicate each of the four assays depicted.

Figure 2

Association between ADCVI antibody activity and superinfection status. Plasma samples were tested at a dilution of 1:100 against CEM.NKR-CCR5 cells infected with either HIV-1_BS208.B1 (A) or HIV-1_Q23XhoΔXho (B) in two separate experiments and with different effector cell donors. Each plasma sample was run in triplicate each of the four assays depicted. There are no significant differences between superinfected subjects (cases) and singly infected subjects (controls).

Figure 2

Association between ADCVI antibody activity and superinfection status. Plasma samples were tested at a dilution of 1:100 against CEM.NKR-CCR5 cells infected with either HIV-1_BS208.B1 (A) or HIV-1_Q23XhoΔXho (B) in two separate experiments and with different effector cell donors. Each plasma sample was run in triplicate each of the four assays depicted. There are no significant differences between superinfected subjects (cases) and singly infected subjects (controls).